Krystal Biotech (KRYS) Asset Writedowns and Impairment (2021)

Krystal Biotech (KRYS) reported Asset Writedowns and Impairment of $1.5 million for Q1 2021.

Krystal Biotech (KRYS) Asset Writedowns and Impairment (2021) Analysis & Trends

Krystal Biotech (KRYS) has 1 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q1 2021.

For the quarter ending Q1 2021, Asset Writedowns and Impairment changed N/A year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2021 stood at $1.5 million (changed N/A YoY), and the FY2021 full-year result was $1.5 million, changed N/A from the prior year.
Asset Writedowns and Impairment held at $1.5 million in Q1 2021.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.5 million in Q1 2021 to a low of $1.5 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,681.27 Bn	66,680.98 Bn	-
2	Nanobiotix	1,905.61 Bn	1,905.55 Bn	-
3	Akari Therapeutics	1,011.81 Bn	1,011.81 Bn	-
4	BeOne Medicines	467.29 Bn	462.50 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.89 Bn	115.65 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.28 Bn	61.53 Bn	3.31 Bn
7	Belite Bio	62.93 Bn	62.93 Bn	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.64 Bn	34.63 Bn	959.66 Mn
10	Krystal Biotech	9.82 Bn	9.00 Bn	110.08 Mn

Download Data

Date	Value
Mar 31, 2021	1.49 Mn
Mar 31, 2021	1.49 Mn